Financial Contrast: Baxter International (NYSE:BAX) and Anteris Technologies Global (NASDAQ:AVR)

Anteris Technologies Global (NASDAQ:AVR) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Volatility and Risk

Anteris Technologies Global has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

90.2% of Baxter International shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Anteris Technologies Global and Baxter International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1	0	4	0	2.60
Baxter International	2	9	2	0	2.00

Anteris Technologies Global presently has a consensus price target of $16.00, indicating a potential upside of 107.52%. Baxter International has a consensus price target of $22.45, indicating a potential downside of 4.37%. Given Anteris Technologies Global’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than Baxter International.

Profitability

This table compares Anteris Technologies Global and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
Baxter International	-9.27%	16.57%	5.24%

Valuation & Earnings

This table compares Anteris Technologies Global and Baxter International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91 million	393.41	-$94.14 million	($1.95)	-3.95
Baxter International	$11.24 billion	1.08	-$957.00 million	($2.07)	-11.34

Anteris Technologies Global has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Summary

Anteris Technologies Global beats Baxter International on 9 of the 14 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.